High flow nasal therapy (HFNT), which utilises a variable air-oxygen mixture at flow rates of greater than 20 litres/min, is shown to be beneficial in a variety of clinical scenarios. This is an evolving field supported by strong biological rationale but the evidence for its use depends on the clinical condition for which it is introduced. The nebuliser - oxygen delivery device interface is an essential extension of the introduction of HFNT due to the high frequency of conmitant use of both technologies and the impact of the oxygen delivery device on drug deposition. Synthesising and summarising current evidence is crucial for clinical practioners to deliver evidence based care. Additionally, casting a spotlight on research gaps will spur the clinical and research community to action and improve the knowledge base in this key area.
HFNT is currently proposed for acute type 1 respiratory failure and increasingly for type 2 respiratory failure. The evidence for its use varies dependent on the clinical condition. Dissecting the evidence on the basis of the clinical condition will provide more specific information for the clinician to then apply in their clinical practice. Highlighting the research gaps will also drive high quality research into this field and improve the evidence base.
This edition will focus on two intersecting topics, high flow nasal therapy (HFNT) and nebuliser technology. Article types that will be accepted are narrative, concise or systematic reviews and randomised controlled trials. Case reports, case series and observational studies will not be accepted.
Articles focused on HFNT summarising clinical evidence for the use of high flow nasal therapy in acute or chronic respiratory failure (type 1 or type 2). The setting could be secondary or domiciliary care.
Articles on nebuliser technology should explore newer options such as ultrasonic and mesh nebulisers, and evidence for their use in patients with HFNT or intubated mechanically ventilated patients, with emphasis on evidence on drug delivery/technology comparisons. The studies could be narrative reviews and include bench side models, healthy volunteers or patient populations.
High flow nasal therapy (HFNT), which utilises a variable air-oxygen mixture at flow rates of greater than 20 litres/min, is shown to be beneficial in a variety of clinical scenarios. This is an evolving field supported by strong biological rationale but the evidence for its use depends on the clinical condition for which it is introduced. The nebuliser - oxygen delivery device interface is an essential extension of the introduction of HFNT due to the high frequency of conmitant use of both technologies and the impact of the oxygen delivery device on drug deposition. Synthesising and summarising current evidence is crucial for clinical practioners to deliver evidence based care. Additionally, casting a spotlight on research gaps will spur the clinical and research community to action and improve the knowledge base in this key area.
HFNT is currently proposed for acute type 1 respiratory failure and increasingly for type 2 respiratory failure. The evidence for its use varies dependent on the clinical condition. Dissecting the evidence on the basis of the clinical condition will provide more specific information for the clinician to then apply in their clinical practice. Highlighting the research gaps will also drive high quality research into this field and improve the evidence base.
This edition will focus on two intersecting topics, high flow nasal therapy (HFNT) and nebuliser technology. Article types that will be accepted are narrative, concise or systematic reviews and randomised controlled trials. Case reports, case series and observational studies will not be accepted.
Articles focused on HFNT summarising clinical evidence for the use of high flow nasal therapy in acute or chronic respiratory failure (type 1 or type 2). The setting could be secondary or domiciliary care.
Articles on nebuliser technology should explore newer options such as ultrasonic and mesh nebulisers, and evidence for their use in patients with HFNT or intubated mechanically ventilated patients, with emphasis on evidence on drug delivery/technology comparisons. The studies could be narrative reviews and include bench side models, healthy volunteers or patient populations.
